Vicarious Surgical (RBOTW) EBITDA (2020 - 2025)

Vicarious Surgical (RBOTW) has 6 years of EBITDA data on file, last reported at -$11.0 million in Q3 2025.

• EBITDA for Q3 2025 came in at -$11.0 million, up 34.68% year-over-year; the trailing twelve-month figure through Sep 2025 was -$53.7 million (up 13.64% YoY), and the FY2024 annual result was -$63.2 million, up 11.09% from the prior year.
• EBITDA advanced to -$11.0 million in Q3 2025 per RBOTW's latest filing, from -$13.2 million in the prior quarter.
• Over five years, EBITDA peaked at $42.5 million in Q1 2022 and troughed at -$26.9 million in Q1 2023.
• A 5-year average of -$10.9 million and a median of -$14.0 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2021 and 2022: EBITDA sank 24660.34% in 2021, then jumped 912.98% in 2022.
• A 5-year view of EBITDA shows it stood at -$17.8 million in 2021, then surged by 37.26% to -$11.2 million in 2022, then fell by 16.39% to -$13.0 million in 2023, then fell by 7.59% to -$14.0 million in 2024, then advanced by 21.07% to -$11.0 million in 2025.
• Business Quant data shows RBOTW's EBITDA at -$11.0 million in Q3 2025, -$13.2 million in Q2 2025, and -$15.4 million in Q1 2025.